A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Registration Number
- NCT04988295
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in participants with locally advanced or metastatic epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution non-small cell lung cancer (NSCLC) after osimertinib failure. The purpose of the extension cohort is to further describe the safety and efficacy for the ACP-L dosing schedule versus ACP with additional data. After completion of the primary analysis, the study may eventually transition to an open-label extension (OLE) or long-term extension (LTE) phase during which participants will have the option to continue their assigned treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 776
- Participant must have at least 1 measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, that has not been previously irradiated
- Participant must have histologically or cytologically confirmed, locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC), characterized at or after the time of locally advanced or metastatic disease diagnosis by either epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R mutation
- A participant with a history of brain metastases must have had all lesions treated as clinically indicated (that is, no current indication for further definitive local therapy). Any definitive local therapy to brain metastases must have been completed at least 14 days prior to randomization and the participant can be receiving no greater than10 milligrams (mg) prednisone or equivalent daily for the treatment of intracranial disease
- Participant must have Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
- Any toxicities from prior systemic anticancer therapy must have resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 Grade 1 or baseline level (except for alopecia [any grade], Grade <= 2 peripheral neuropathy, or Grade <= 2 hypothyroidism stable on hormone replacement)
- A participant of childbearing potential must have a negative serum pregnancy test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study
- Participant must have progressed on or after osimertinib monotherapy as the most recent line of treatment. Osimertinib must have been administered as either the first-line treatment for locally advanced or metastatic disease or in the second- line setting after prior treatment with first- or second-generation EGFR tyrosine kinase inhibitor (TKI) as a monotherapy. Participants who received either neoadjuvant and/or adjuvant treatment of any type are eligible if progression to locally advanced or metastatic disease occurred at least 12 months after the last dose of such therapy and then the participant progressed on or after osimertinib in the locally advanced or metastatic setting. Treatment with osimertinib must be discontinued at least 8 days (4 half-lives) prior to randomization (that is last dose no later than Day -8)
- Participant received radiotherapy for palliative treatment of NSCLC less than 14 days prior to randomization
- Participant with symptomatic or progressive brain metastases
- Participant has history of or current evidence of leptomeningeal disease, or participant has spinal cord compression not definitively treated with surgery or radiation
- Participant has known small cell transformation
- Participant has a medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis
- Participant has a history of clinically significant cardiovascular disease including, but not limited to diagnosis of deep vein thrombosis or pulmonary embolism within 4 weeks prior to randomization; myocardial infarction; unstable angina; stroke; transient ischemic attack; coronary/peripheral artery bypass graft; or acute coronary syndrome. Participant has a significant genetic predisposition to venous thromboembolic events. Participant has a prior history of venous thromboembolic events and is not on appropriate therapeutic anticoagulation as per National Comprehensive Cancer Network or local guidelines
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm C: ACP (Amivantamab, Carboplatin and Pemetrexed) Amivantamab Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression. Arm C: ACP (Amivantamab, Carboplatin and Pemetrexed) Pemetrexed Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression. Arm A: LACP/ACP-L Lazertinib LACP dosing (study start until 6 November 2022): Participants will receive Lazertinib orally along with Amivantamab, Pemetrexed, and Carboplatin as IV infusion starting on Cycle 1 Day 1 for 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression. ACP-L dosing (from 7 November 2022 until study completion): Participants will receive Amivantamab, Pemetrexed, and Carboplatin starting on Cycle 1 Day 1 for 4 cycles. Lazertinib in ACP-L will start on Cycle 5 Day 1 or sooner if carboplatin is discontinued before cycle 4 (each cycle consists of 21 days). Beginning with Cycle 5 Day 1, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression. Arm A: LACP/ACP-L Pemetrexed LACP dosing (study start until 6 November 2022): Participants will receive Lazertinib orally along with Amivantamab, Pemetrexed, and Carboplatin as IV infusion starting on Cycle 1 Day 1 for 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression. ACP-L dosing (from 7 November 2022 until study completion): Participants will receive Amivantamab, Pemetrexed, and Carboplatin starting on Cycle 1 Day 1 for 4 cycles. Lazertinib in ACP-L will start on Cycle 5 Day 1 or sooner if carboplatin is discontinued before cycle 4 (each cycle consists of 21 days). Beginning with Cycle 5 Day 1, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression. Arm A: LACP/ACP-L Carboplatin LACP dosing (study start until 6 November 2022): Participants will receive Lazertinib orally along with Amivantamab, Pemetrexed, and Carboplatin as IV infusion starting on Cycle 1 Day 1 for 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression. ACP-L dosing (from 7 November 2022 until study completion): Participants will receive Amivantamab, Pemetrexed, and Carboplatin starting on Cycle 1 Day 1 for 4 cycles. Lazertinib in ACP-L will start on Cycle 5 Day 1 or sooner if carboplatin is discontinued before cycle 4 (each cycle consists of 21 days). Beginning with Cycle 5 Day 1, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression. Arm B: CP (Carboplatin and Pemetrexed) Pemetrexed Participants will receive Pemetrexed in combination with Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Pemetrexed as maintenance until disease progression. Arm B: CP (Carboplatin and Pemetrexed) Carboplatin Participants will receive Pemetrexed in combination with Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Pemetrexed as maintenance until disease progression. Arm C: ACP (Amivantamab, Carboplatin and Pemetrexed) Carboplatin Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression. Arm A2 (Extension Cohort): ACP-L Lazertinib Participants will receive Amivantamab, Pemetrexed and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days), Lazertinib will start on C5D1 or sooner if carboplatin is discontinued earlier). After 4 cycles, participants will receive Pemetrexed, Amivantamab, Lazertinib as maintenance until disease progression. Arm A2 (Extension Cohort): ACP-L Pemetrexed Participants will receive Amivantamab, Pemetrexed and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days), Lazertinib will start on C5D1 or sooner if carboplatin is discontinued earlier). After 4 cycles, participants will receive Pemetrexed, Amivantamab, Lazertinib as maintenance until disease progression. Arm A2 (Extension Cohort): ACP-L Carboplatin Participants will receive Amivantamab, Pemetrexed and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days), Lazertinib will start on C5D1 or sooner if carboplatin is discontinued earlier). After 4 cycles, participants will receive Pemetrexed, Amivantamab, Lazertinib as maintenance until disease progression. Arm C2 (Extension Cohort): ACP Pemetrexed Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression. Arm C2 (Extension Cohort): ACP Carboplatin Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression. Arm C2 (Extension Cohort): ACP Amivantamab Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression. Arm A: LACP/ACP-L Amivantamab LACP dosing (study start until 6 November 2022): Participants will receive Lazertinib orally along with Amivantamab, Pemetrexed, and Carboplatin as IV infusion starting on Cycle 1 Day 1 for 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression. ACP-L dosing (from 7 November 2022 until study completion): Participants will receive Amivantamab, Pemetrexed, and Carboplatin starting on Cycle 1 Day 1 for 4 cycles. Lazertinib in ACP-L will start on Cycle 5 Day 1 or sooner if carboplatin is discontinued before cycle 4 (each cycle consists of 21 days). Beginning with Cycle 5 Day 1, participants will receive Amivantamab, Pemetrexed and Lazertinib as maintenance until disease progression. Arm A2 (Extension Cohort): ACP-L Amivantamab Participants will receive Amivantamab, Pemetrexed and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days), Lazertinib will start on C5D1 or sooner if carboplatin is discontinued earlier). After 4 cycles, participants will receive Pemetrexed, Amivantamab, Lazertinib as maintenance until disease progression.
- Primary Outcome Measures
Name Time Method Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months) PFS is defined as the time from randomization until the date of objective disease progression or death, whichever came first, as assessed by BICR according to RECIST version 1.1. Progressed disease: Sum of diameters increased by greater than or equal to (\>=)20 percent (%) and \>=5 millimeter (mm) from nadir (including baseline if it was smallest sum).
Main Study + Extension Cohort: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) up to 4 years 10 months Follow-up for the extension cohort is still ongoing and thus results from the analysis that includes the extension cohort will be reported up on study completion.
Main Study + Extension Cohort: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review Up to 4 years 10 months
- Secondary Outcome Measures
Name Time Method Main Study+ Extension Cohort: Overall Survival Up to 4 years 10 months Main Study+ Extension Cohort: Objective Response Rate as Assessed by Blinded Independent Central Review Up to 4 years 10 months Main Study+ Extension Cohort: Duration of Response as Assessed by Blinded Independent Central Review Up to 4 years 10 months Main Study+ Extension Cohort: Time to Subsequent Therapy Up to 4 years 10 months Main Study+ Extension Cohort: Progression-free Survival (PFS) After First Subsequent Therapy (PFS2) Up to 4 years 10 months Main Study+ Extension Cohort: Time to Symptomatic Progression Up to 4 years 10 months Main Study+ Extension Cohort: Intracranial Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review Up to 4 years 10 months Main Study: Number of Participants With Adverse Events (AEs) Up to 4 years 10 months Main Study+ Extension Cohort: Number of Participants With Adverse Events (AEs) by Severity Up to 4 years 10 months Main Study+ Extension Cohort: Number of Participants With Clinical Laboratory Abnormalities Up to 4 years 10 months Main Study+ Extension Cohort: Serum Concentration of Amivantamab Up to 4 years 10 months Main Study+ Extension Cohort: Plasma Concentration of Lazertinib Up to 4 years 10 months Main Study + Extension Cohort: Number of Participants With Serum Anti-amivantamab Antibodies Up to 4 years 10 months Main Study+ Extension Cohort: Change From Baseline With Non-Small Cell Lung Cancer - Symptom Assessment Questionnaire (NSCLC-SAQ) Up to 4 years 10 months Main Study+ Extension Cohort: Change From Baseline With European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) Up to 4 years 10 months Main Study+ Extension Cohort: Change From Baseline With Patient-Reported Outcomes Measurement Information System -Physical Function (PROMIS-PF) Up to 4 years 10 months
Trial Locations
- Locations (247)
Baptist Cancer Center
🇺🇸Memphis, Tennessee, United States
Texas Oncology-Medical City Dallas
🇺🇸Dallas, Texas, United States
Texas Oncology Baylor Charles A Sammons Cancer Center
🇺🇸Dallas, Texas, United States
Texas Oncology
🇺🇸Grapevine, Texas, United States
Oncology Consultants Texas
🇺🇸Houston, Texas, United States
Texas Oncology - Northeast
🇺🇸Longview, Texas, United States
University of Vermont Medical Center
🇺🇸Burlington, Vermont, United States
University of Virginia
🇺🇸Charlottesville, Virginia, United States
Virginia Cancer Specialists
🇺🇸Fairfax, Virginia, United States
Blue Ridge Cancer Care
🇺🇸Wytheville, Virginia, United States
Pan American Center for Oncology Trials LLC
🇵🇷Rio Piedras, Puerto Rico
City Clinical Hospital #1
🇷🇺Nalchik, Russian Federation
Llc, Eurocityclinic
🇷🇺Saint Petersburg, Russian Federation
Hosp Univ A Coruna
🇪🇸A Coruña, Spain
National Hospital Organization Shibukawa Medical Center
🇯🇵Gunma, Japan
Hyogo Cancer Center
🇯🇵Hyogo, Japan
Kanagawa Cancer Center
🇯🇵Kanagawa, Japan
Norrlands Universitetssjukhus
🇸🇪Umea, Sweden
Akademiska Sjukhuset
🇸🇪Uppsala, Sweden
CHU de Grenoble Hopital Albert Michallon
🇫🇷La Tronche, France
Southern Cancer Center, PC
🇺🇸Mobile, Alabama, United States
Arizona Oncology Associates
🇺🇸Tucson, Arizona, United States
Centre Hospitalier du Mans
🇫🇷le Mans, France
City of Hope
🇺🇸Duarte, California, United States
Cedars Sinai Medical Center
🇺🇸Los Angeles, California, United States
University of California Irvine
🇺🇸Orange, California, United States
Rocky Mountain Cancer Centers
🇺🇸Colorado Springs, Colorado, United States
Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center
🇺🇸Fort Lauderdale, Florida, United States
University Cancer And Blood Center LLC
🇺🇸Athens, Georgia, United States
University of Mississippi Medical Center
🇺🇸Jackson, Mississippi, United States
Nebraska Cancer Specialists
🇺🇸Grand Island, Nebraska, United States
Astera Cancer Care
🇺🇸East Brunswick, New Jersey, United States
TriHealth Network
🇺🇸Cincinnati, Ohio, United States
Providence Portland Medical Center
🇺🇸Portland, Oregon, United States
Kaiser Permanente Northwest
🇺🇸Portland, Oregon, United States
Alliance Cancer Specialists
🇺🇸Horsham, Pennsylvania, United States
University of Pittsburgh Medical Center
🇺🇸Pittsburgh, Pennsylvania, United States
NorthWest Medical Specialties, PLLC
🇺🇸Puyallup, Washington, United States
Compass Oncology
🇺🇸Vancouver, Washington, United States
CINME Centro de Investigaciones Metabolicas
🇦🇷Caba, Argentina
IADT Instituto Argentino de Diagnostico y Tratamiento
🇦🇷Caba, Argentina
Centro Medico Fleischer
🇦🇷Caba, Argentina
CEMIC (Centro de Educación Médica e Investigaciones Clínicas)
🇦🇷Caba, Argentina
Hospital Privado Universitario De Cordoba
🇦🇷Cordoba, Argentina
Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
🇦🇷Córdoba, Argentina
Hospital Privado de la Comunidad
🇦🇷Mar del Plata, Argentina
Clínica Viedma
🇦🇷Viedma, Argentina
Grand Hopital De Charleroi Site Les Viviers
🇧🇪Charleroi, Belgium
UZA
🇧🇪Edegem, Belgium
UZ Gent
🇧🇪Gent, Belgium
Jessa Ziekenhuis - Campus Virga Jesse
🇧🇪Hasselt, Belgium
UZ Leuven
🇧🇪Leuven, Belgium
CHU Sart-Tilman
🇧🇪Liege, Belgium
Clinique Saint Pierre
🇧🇪Ottignies, Belgium
Cetus Oncologia
🇧🇷Belo Horizonte, Brazil
CIONC Centro Integrado de Oncologia de Curitiba
🇧🇷Curitiba, Brazil
Ynova Pesquisa Clinica
🇧🇷Florianopolis, Brazil
Fundação São Francisco Xavier
🇧🇷Ipatinga, Brazil
UPCO Unidade de Pesquisa Clinica em Oncologia
🇧🇷Pelotas, Brazil
Associacao Hospitalar Moinhos de Vento
🇧🇷Porto Alegre, Brazil
Hospital Ernesto Dornelles
🇧🇷Porto Alegre, Brazil
Oncoclinicas Rio de Janeiro S A
🇧🇷Rio de Janeiro, Brazil
Instituto D Or de Pesquisa e Ensino IDOR
🇧🇷Rio de Janeiro, Brazil
Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
🇧🇷Rio de Janeiro, Brazil
Nucleo de Oncologia da Bahia
🇧🇷Salvador, Brazil
Hospital Sao Rafael
🇧🇷Salvador, Brazil
CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
🇧🇷Santo Andre, Brazil
Real e Benemerita Associacao Portuguesa de Beneficencia
🇧🇷Sao Paulo, Brazil
Hospital Paulistano
🇧🇷Sao Paulo, Brazil
Hospital Alemao Oswaldo Cruz
🇧🇷Sao Paulo, Brazil
Fundacao Antonio Prudente A C Camargo Cancer Center
🇧🇷Sao Paulo, Brazil
Onco Star SP Oncologia Ltda
🇧🇷Sao Paulo, Brazil
IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado
🇧🇷Sorocaba, Brazil
Multifunctional Hospital for Active Treatment 'Serdika'
🇧🇬Sofia, Bulgaria
Multiprofile Hospital for Active Treatment 'Tokuda Hospital Sofia'
🇧🇬Sofia, Bulgaria
Hospital Nove de Julho
🇧🇷São Paulo, Brazil
COT - Centro Oncologico do Triangulo S.A
🇧🇷Uberlandia, Brazil
Specialized Hospital for Active Treatment in Oncology
🇧🇬Sofia, Bulgaria
UMHAT Sofia Med
🇧🇬Sofia, Bulgaria
Arthur J E Child Comprehensive Cancer Centre
🇨🇦Calgary, Alberta, Canada
British Columbia Cancer Agency
🇨🇦Vancouver, British Columbia, Canada
McGill University Health Centre
🇨🇦Montreal, Quebec, Canada
Cancer Hospital, Chinese Academy of Medical Sciences
🇨🇳Beijing, China
Peking University People s Hospital
🇨🇳Beijing, China
Beijing Cancer Hospital
🇨🇳Beijing, China
Chinese PLA General Hospital
🇨🇳Beijing, China
Beijing Chest hospital, Capital medical university
🇨🇳Beijing, China
Hunan Cancer hospital
🇨🇳Changsha, China
Sichuan Cancer Hospital
🇨🇳Chengdu, China
West China Hospital Sichuan University
🇨🇳Chengdu, China
CHR Hôpital Calmette
🇫🇷Lille, France
Chongqing University Cancer Hospital
🇨🇳Chongqing, China
Southwest Hospital
🇨🇳ChongQing, China
The First Affiliated Hospital Sun Yat sen University
🇨🇳Guang Zhou, China
Sun Yat-Sen Memorial Hospital Sun Yat-sen University
🇨🇳Guangzhou, China
Zhejiang Cancer Hospital
🇨🇳Hang Zhou, China
Second Affiliated Hospital, School of Medicine, Zhejiang University
🇨🇳Hangzhou, China
The Second Affiliated Hospital of Zhejiang University College of Medicine
🇨🇳Hangzhou, China
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
🇨🇳Hangzhou, China
Harbin medical university cancer hospital
🇨🇳Harbin, China
Huizhou Municipal Central Hospital
🇨🇳Huizhou, China
Taizhou Hospital of Zhejiang Province
🇨🇳Linhai, China
Affiliated Hospital of North Sichuan Medical College
🇨🇳Nanchong, China
Ruijin Hospital Shanghai Jiao Tong University
🇨🇳Shanghai, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
Shanghai East Hospital
🇨🇳Shanghai, China
Shenzhen university General Hospital
🇨🇳Shenzhen, China
Cancer Hospital Chinese Academy of Medical Sciences
🇨🇳Shenzhen, China
Tianjin Medical University General Hospital
🇨🇳Tianjin, China
Weifang People's Hospital
🇨🇳Weifang, China
The First Affiliated Hospital of Xian Jiaotong University
🇨🇳XI An, China
Yantai Yuhuangding Hospital
🇨🇳Yantai, China
Daping Hospital Army Characteristic Medical Center
🇨🇳Yuzhong District, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Fakultni nemocnice Olomouc - I.P.Pavlova 6
🇨🇿Olomouc, Czechia
Vitkovicka nemocnice a.s.
🇨🇿Ostrava- Vitkovice, Czechia
Fakultni nemocnice Plzen
🇨🇿Plzen, Czechia
Rigshospitalet
🇩🇰Copenhagen, Denmark
Institut Sainte Catherine
🇫🇷Avignon Cedex 9, France
Hospices Civils de Lyon HCL
🇫🇷Bron, France
Hopital Nord
🇫🇷Marseille Cedex 20, France
CHU de Montpellier - Arnaud de Villeneuve
🇫🇷Montpellier Cedex 5, France
Institut Curie
🇫🇷Paris, France
CHU Bordeaux
🇫🇷Pessac, France
CHRU Hopital de Pontchaillou
🇫🇷Rennes, France
CHU Nantes
🇫🇷Sain-Herblain, France
Nouvel Hopital Civil - CHU Strasbourg
🇫🇷Strasbourg cedex, France
CHU Bretonneau
🇫🇷Tours, France
Evangelische Lungenklinik Berlin
🇩🇪Berlin, Germany
Asklepios Klinikum Harburg
🇩🇪Hamburg, Germany
Thoraxklinik am Universitatsklinikum Heidelberg
🇩🇪Heidelberg, Germany
Onkologische Schwerpunktpraxis
🇩🇪Heilbronn, Germany
POIS Sachsen GmbH iG
🇩🇪Leipzig, Germany
Bethanien Krankenhaus
🇩🇪Moers, Germany
Klinikum der Universitaet Muenchen
🇩🇪München, Germany
Oncologianova GmbH
🇩🇪Recklinghausen, Germany
Universitaetsklinikum Regensburg
🇩🇪Regensburg, Germany
Queen Mary Hospital
🇭🇰Hong Kong, Hong Kong
Health Care Global Enterprises pvt Ltd
🇮🇳Bangalore, India
Artemis Hospital
🇮🇳Gurugram, India
Tata Medical Center
🇮🇳Kolkata, India
Tata Memorial Hospital
🇮🇳Mumbai, India
HCG Manavta Cancer Centre
🇮🇳Nasik, India
Rajiv Gandhi Cancer Institute and Research Centre
🇮🇳New Delh, India
Noble Hospital Pvt Ltd
🇮🇳Pune, India
Bhaktivedanta Hospital & Research Institute
🇮🇳Thane, India
Soroka University Medical Center
🇮🇱Beersheba, Israel
Rambam Health Corporation
🇮🇱Haifa, Israel
Shaare Zedek Medical Center
🇮🇱Jerusalem, Israel
Meir Medical Center
🇮🇱Kfar Saba, Israel
Rabin Medical Center
🇮🇱Petah Tikva, Israel
Chaim Sheba Medical Center
🇮🇱Ramat Gan, Israel
Tel Aviv Sourasky Medical Center
🇮🇱Tel-Aviv, Israel
CRO IRCCS Istituto Nazionale Tumori
🇮🇹Aviano, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
🇮🇹Meldola, Italy
Istituto Europeo di Oncologia
🇮🇹Milano, Italy
Azienda Ospedaliero-Universitaria Di Parma
🇮🇹Parma, Italy
Ospedale S. Maria Delle Croci
🇮🇹Ravenna, Italy
Istituto Nazionale Tumori Regina Elena
🇮🇹Roma, Italy
Policlinico G.B.Rossi
🇮🇹Verona, Italy
Kobe City Medical Center General Hospital
🇯🇵Kobe City, Japan
Kurume University Hospital
🇯🇵Kurume, Japan
National Hospital Organization Nagoya Medical Center
🇯🇵Nagoya-shi, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
Osaka International Cancer Institute
🇯🇵Osaka City, Japan
Shizuoka Cancer Center
🇯🇵Shizuoka, Japan
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
🇯🇵Tokyo, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
Ehime University Hospital
🇯🇵Toon-shi, Japan
Wakayama Medical University Hospital
🇯🇵Wakayama, Japan
National Hospital Organization Iwakuni Clinical Center
🇯🇵Yamaguchi, Japan
National Hospital Organization Yamaguchi Ube Medical Center
🇯🇵Yamaguchi, Japan
National Cancer Center
🇰🇷Gyeonggi-do, Korea, Republic of
CHA Bundang Medical Center, CHA University
🇰🇷Gyeonggi-do, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Gyeonggi-do, Korea, Republic of
GyeongSang National University Hospital
🇰🇷Gyeongsangnam-do, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea Seoul St Mary s Hospital
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Beacon Hospital Sdn Bhd
🇲🇾Petaling Jaya, Malaysia
Subang Jaya Medical Centre
🇲🇾Subang Jaya, Malaysia
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
University Malaya Medical Centre
🇲🇾Kuala Lumpur, Malaysia
Hospital Tengku Ampuan Afzan
🇲🇾Kuantan, Malaysia
Mount Miriam Cancer Hospital
🇲🇾Tanjung Bungah, Malaysia
Hospital Civil de Guadalajara Fray Antonio Alcalde
🇲🇽Guadalajara, Mexico
CIMOVA, Morals Vargas Centro de Investigación SC
🇲🇽Leon, Mexico
Health Pharma Professional Research
🇲🇽Mexico, Mexico
Instituto Nacional de Cancerologia
🇲🇽Mexico, Mexico
Oncologia Integral Satelite
🇲🇽Naucalpan, Mexico
VUMC Amsterdam
🇳🇱Amsterdam, Netherlands
Ziekenhuis St Jansdal
🇳🇱Harderwijk, Netherlands
Erasmus MC
🇳🇱Rotterdam, Netherlands
Centrum Onkologii im Prof F Lukaszczyka
🇵🇱Bydgoszcz, Poland
Uniwersyteckie Centrum Kliniczne
🇵🇱Gdansk, Poland
Szpitale Pomorskie Sp z o o
🇵🇱Gdynia, Poland
Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie
🇵🇱Olsztyn, Poland
Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandow
🇵🇱Poznan, Poland
Private Specialist Hospitals - MedPolonia
🇵🇱Poznan, Poland
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
🇵🇱Warszawa, Poland
Uls Santa Maria - Hosp. Pulido Valente
🇵🇹Lisboa, Portugal
Uls Loures Odivelas - Hosp. Loures
🇵🇹Loures, Portugal
Uls Santo Antonio - Hosp. Santo Antonio
🇵🇹Porto, Portugal
Instituto Portugues de Oncologia
🇵🇹Porto, Portugal
Hosp. de La Santa Creu I Sant Pau
🇪🇸Barcelona, Spain
Hosp. Univ. Quiron Dexeus
🇪🇸Barcelona, Spain
Hosp Univ Vall D Hebron
🇪🇸Barcelona, Spain
Hosp Clinic de Barcelona
🇪🇸Barcelona, Spain
Hosp. Univ. Insular de Gran Canaria
🇪🇸Las Palmas de Gran Canaria, Spain
Hosp. Gral. Univ. Gregorio Maranon
🇪🇸Madrid, Spain
Hosp Univ Fund Jimenez Diaz
🇪🇸Madrid, Spain
Hosp. Univ. 12 de Octubre
🇪🇸Madrid, Spain
Hosp. Univ. La Paz
🇪🇸Madrid, Spain
Hosp Univ Hm Sanchinarro
🇪🇸Madrid, Spain
Hosp. Univ. Pta. de Hierro Majadahonda
🇪🇸Majadahonda, Spain
Hosp Regional Univ de Malaga
🇪🇸Málaga, Spain
Clinica Univ. de Navarra
🇪🇸Pamplona, Spain
Hosp. Virgen Del Rocio
🇪🇸Seville, Spain
Hosp. Gral. Univ. Valencia
🇪🇸Valencia, Spain
Hosp. Univ. I Politecni La Fe
🇪🇸Valencia, Spain
Sahlgrenska Universitetssjukhuset
🇸🇪Goteborg, Sweden
Linkoping University Hospital
🇸🇪Linkoping, Sweden
Skanes universitetssjukhus
🇸🇪Lund, Sweden
Changhua Christian Hospital
🇨🇳Changhua, Taiwan
Kaohsiung Medical University Chung Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Taipei Medical University Shuang Ho Hospital
🇨🇳New Taipei City, Taiwan
Chung Shan Medical University Hospital
🇨🇳Taichung, Taiwan
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Adana City Hospital
🇹🇷Adana, Turkey
Memorial Ankara Hastanesi
🇹🇷Ankara, Turkey
Gazi University Hospital
🇹🇷Ankara, Turkey
Ankara Bilkent City Hospital
🇹🇷Ankara, Turkey
Trakya University Medical Faculty
🇹🇷Edirne, Turkey
Istanbul University Cerrahpasa Medical Faculty
🇹🇷Istanbul, Turkey
Bakirkoy Training and Research Hospital
🇹🇷Istanbul, Turkey
Medipol Mega University Hospital
🇹🇷Istanbul, Turkey
Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi
🇹🇷Istanbul, Turkey
Medical Point
🇹🇷Izmir, Turkey
Velindre Hospital
🇬🇧Cardiff, United Kingdom
Edinburgh Cancer Centre Western General
🇬🇧Edinburgh, United Kingdom
UCL Cancer Institute
🇬🇧London, United Kingdom
Guys and St Thomas NHS Foundation Trust
🇬🇧London, United Kingdom
The Royal Marsden NHS Trust
🇬🇧London, United Kingdom
The Christie Nhs Foundation Trust
🇬🇧Manchester, United Kingdom